Organizational Readiness for Change and opinions toward treatment innovations.

Moving innovations into treatment: A stage-based approach to program change. J Subst Abuse Treat (2007) 2.94

Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review. J Subst Abuse Treat (2008) 2.42

Linking the elements of change: Program and client responses to innovation. J Subst Abuse Treat (2007) 1.99

Strategies for training counselors in evidence-based treatments. Addict Sci Clin Pract (2010) 1.70

Methods and metrics challenges of delivery-system research. Implement Sci (2012) 1.49

Partnerships and pathways of dissemination: the National Institute on Drug Abuse-Substance Abuse and Mental Health Services Administration Blending Initiative in the Clinical Trials Network. J Subst Abuse Treat (2010) 1.19

Contingency management in substance abuse treatment: a structured review of the evidence for its transportability. Drug Alcohol Depend (2011) 1.14

Supervisory turnover in outpatient substance abuse treatment. J Behav Health Serv Res (2009) 1.01

Organizational capacity for service integration in community-based addiction health services. Am J Public Health (2014) 0.97

Empirically Supported Treatment's Impact on Organizational Culture and Climate. Res Soc Work Pract (2012) 0.96

Comparing credentialing requirements of substance abuse treatment staff by funding source. J Subst Abuse Treat (2007) 0.94

Organizational implementation of evidence-based substance abuse treatment in racial and ethnic minority communities. Adm Policy Ment Health (2014) 0.94

Association of intervention outcomes with practice capacity for change: subgroup analysis from a group randomized trial. Implement Sci (2008) 0.89

Dimensions of community and organizational readiness for change. Prog Community Health Partnersh (2012) 0.88

A multilevel approach to predicting community addiction treatment attitudes about contingency management. J Subst Abuse Treat (2011) 0.88

System-level effects of integrating a promising treatment into juvenile drug courts. J Subst Abuse Treat (2011) 0.88

Community-based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. Eval Program Plann (2011) 0.87

Advancing recovery: implementing evidence-based treatment for substance use disorders at the systems level. J Stud Alcohol Drugs (2012) 0.86

Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav (2011) 0.86

Disseminating contingency management: impacts of staff training and implementation at an opiate treatment program. J Subst Abuse Treat (2013) 0.85

A systematic review of instruments to assess organizational readiness for knowledge translation in health care. PLoS One (2014) 0.85

Organizational Readiness for Change in Correctional and Community Substance Abuse Programs. J Offender Rehabil (2012) 0.84

Relating counselor attributes to client engagement in England. J Subst Abuse Treat (2008) 0.83

Substance abuse treatment and services by criminal justice and other funding sources. Addict Behav (2009) 0.82

CORRELATES OF INTERORGANIZATIONAL SERVICE COORDINATION IN COMMUNITY CORRECTIONS. Crim Justice Behav (2015) 0.81

Organizational factors influencing implementation of evidence-based practices for integrated treatment in behavioral health agencies. Psychiatry J (2014) 0.81

Predicting implementation from organizational readiness for change: a study protocol. Implement Sci (2011) 0.81

The substance abuse counseling workforce: education, preparation, and certification. Subst Abus (2011) 0.80

Training addiction professionals in empirically supported treatments: perspectives from the treatment community. Subst Abus (2014) 0.79

Innovation adoption as facilitated by a change-oriented workplace. J Subst Abuse Treat (2011) 0.79

Building a bonfire that remains stoked: sustainment of a contingency management intervention developed through collaborative design. Subst Abuse Treat Prev Policy (2015) 0.79

Legislating clinical practice: counselor responses to an evidence-based practice mandate. J Psychoactive Drugs (2011) 0.79

Treatment length and outcomes among adolescents: a secondary data analysis. Subst Abuse Treat Prev Policy (2012) 0.78

A multi-level examination of how the organizational context relates to readiness to implement prevention and evidence-based programming in community settings. Eval Program Plann (2015) 0.77

The impact of training interventions on organizational readiness to support innovations in juvenile justice offices. Adm Policy Ment Health (2014) 0.77

Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus (2015) 0.77

Training opioid addiction treatment providers to adopt contingency management: A prospective pilot trial of a comprehensive implementation science approach. Subst Abus (2016) 0.76

Finding harmony so the music plays on: pragmatic trial design considerations to promote organizational sustainment of an empirically-supported behavior therapy. Addict Sci Clin Pract (2016) 0.75

A structural model of treatment program and individual counselor leadership in innovation transfer. BMC Health Serv Res (2017) 0.75

Development and Pilot Test of the Workplace Readiness Questionnaire, a Theory-Based Instrument to Measure Small Workplaces' Readiness to Implement Wellness Programs. Am J Health Promot (2015) 0.75

Transdisciplinary collaboration and endorsement of pharmacological and psychosocial evidence-based practices by medical and psychosocial substance abuse treatment providers in the United States. Drugs (Abingdon Engl) (2013) 0.75

Translation of the Risk Avoidance Partnership (RAP) for Implementation in Outpatient Drug Treatment Clinics. J Psychoactive Drugs (2015) 0.75

Assessing organizational readiness for change. J Subst Abuse Treat (2002) 7.75

Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study. Arch Gen Psychiatry (2005) 6.97

A conceptual framework for transferring research to practice. J Subst Abuse Treat (2002) 6.76

Can the national addiction treatment infrastructure support the public's demand for quality care? J Subst Abuse Treat (2003) 5.97

Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry (2006) 4.64

A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction (2005) 4.14

Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38

The Network for the Improvement of Addiction Treatment (NIATx): enhancing access and retention. Drug Alcohol Depend (2006) 3.38

Moving innovations into treatment: A stage-based approach to program change. J Subst Abuse Treat (2007) 2.94

Staff beliefs about addiction treatment. J Subst Abuse Treat (2001) 2.87

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85

Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer. J Subst Abuse Treat (2004) 1.31

Design and implementation of microarray gene expression markup language (MAGE-ML). Genome Biol (2002) 16.75

Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med (2009) 9.35

A simple spreadsheet-based, MIAME-supportive format for microarray data: MAGE-TAB. BMC Bioinformatics (2006) 7.53

Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA (2002) 6.48

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet (2011) 6.35

Pattern separation in the human hippocampal CA3 and dentate gyrus. Science (2008) 5.56

A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science (2008) 4.50

The first RSBI (ISA-TAB) workshop: "can a simple format work for complex studies?". OMICS (2008) 4.15

The Functional Genomics Experiment model (FuGE): an extensible framework for standards in functional genomics. Nat Biotechnol (2007) 3.55

Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38

Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat (2003) 2.91

Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict (2004) 2.85

Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: results of NIDA Clinical Trials Network Trial. J Acquir Immune Defic Syndr (2008) 2.78

Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend (2005) 2.66

Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend (2007) 2.63

Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology (2003) 2.61

Do treatment improvements in PTSD severity affect substance use outcomes? A secondary analysis from a randomized clinical trial in NIDA's Clinical Trials Network. Am J Psychiatry (2009) 2.44

Multisite randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. J Consult Clin Psychol (2009) 2.26

Behavioral health insurance parity: does Oregon's experience presage the national experience with the Mental Health Parity and Addiction Equity Act? Am J Psychiatry (2011) 2.24

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19

Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther (2004) 2.14

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet (2013) 2.11

Which elements of improvement collaboratives are most effective? A cluster-randomized trial. Addiction (2013) 2.10

Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. J Subst Abuse Treat (2006) 2.08

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01

Making "stone soup": improvements in clinic access and retention in addiction treatment. Jt Comm J Qual Patient Saf (2007) 1.96

The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction (2002) 1.94

Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis (2007) 1.93

Adoption of naltrexone to treat alcohol dependence. J Subst Abuse Treat (2005) 1.84

Replication and sustainability of improved access and retention within the Network for the Improvement of Addiction Treatment. Drug Alcohol Depend (2008) 1.80

Image-based estimation of ventricular fiber orientations for personalized modeling of cardiac electrophysiology. IEEE Trans Med Imaging (2012) 1.72

Cognition, commitment language, and behavioral change among cocaine-dependent patients. Psychol Addict Behav (2008) 1.72

The first decade of the National Drug Abuse Treatment Clinical Trials Network: bridging the gap between research and practice to improve drug abuse treatment. J Subst Abuse Treat (2010) 1.67

Addiction treatment agencies' use of data: a qualitative assessment. J Behav Health Serv Res (2006) 1.66

Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug Alcohol Depend (2007) 1.64

A chloroplast transgenic approach to hyper-express and purify Human Serum Albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol J (2003) 1.64

Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacol Ther (2005) 1.64

Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med (2010) 1.64

Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther (2003) 1.63

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction (2013) 1.63

Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend (2011) 1.62

Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat (2006) 1.61

Rising national prevalence of life-limiting conditions in children in England. Pediatrics (2012) 1.59

Self-help organizations for alcohol and drug problems: toward evidence-based practice and policy. J Subst Abuse Treat (2004) 1.59

Smoking cessation treatment in community-based substance abuse rehabilitation programs. J Subst Abuse Treat (2007) 1.57

Genomewide suggestive linkage of opioid dependence to chromosome 14q. Hum Mol Genet (2007) 1.54

Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia. Nephrol Dial Transplant (2008) 1.52

High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50

ABCA1(Alabama): a novel variant associated with HDL deficiency and premature coronary artery disease. Atherosclerosis (2002) 1.49

Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr (2013) 1.48

Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res (2006) 1.47

In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther (2007) 1.46

Early impact of prescription Omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology (2011) 1.46

Patient satisfaction, prescription drug abuse, and potential unintended consequences. JAMA (2012) 1.45

Zero-inflated and hurdle models of count data with extra zeros: examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse (2011) 1.44

The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophr Res (2007) 1.44

The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease. J Mol Med (Berl) (2006) 1.42

Treating alcohol and drug use disorders. Health Aff (Millwood) (2013) 1.41

Resistance to chronic wasting disease in transgenic mice expressing a naturally occurring allelic variant of deer prion protein. J Virol (2007) 1.41

Internet-delivered treatment for substance abuse: a multisite randomized controlled trial. Am J Psychiatry (2014) 1.40

FuGE: Functional Genomics Experiment Object Model. OMICS (2006) 1.39

Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39

Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network. Contemp Clin Trials (2011) 1.38

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol (2010) 1.36

The Oak Ridge Polycystic Kidney mouse: modeling ciliopathies of mice and men. Dev Dyn (2008) 1.36

Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat (2002) 1.36

Does glycemic variability impact mood and quality of life? Diabetes Technol Ther (2012) 1.35

Lead toxicity in a 14-year-old female with retained bullet fragments. Pediatrics (2006) 1.34

A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients. J Virol (2005) 1.32

A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend (2005) 1.31

Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer. J Subst Abuse Treat (2004) 1.31

Chromosomal location plays a role in regulation of aflatoxin gene expression in Aspergillus parasiticus. Appl Environ Microbiol (2002) 1.31

Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology (2003) 1.31

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay. J Immunol Methods (2004) 1.29

Concussion in professional football: players returning to the same game--part 7. Neurosurgery (2005) 1.28

The impact of trauma-focused group therapy upon HIV sexual risk behaviors in the NIDA Clinical Trials Network "Women and trauma" multi-site study. AIDS Behav (2009) 1.28

Hypertriglyceridemia and cardiovascular risk reduction. Clin Ther (2007) 1.28

Annotare--a tool for annotating high-throughput biomedical investigations and resulting data. Bioinformatics (2010) 1.26

Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend (2008) 1.25

Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther (2005) 1.25

Brief strategic family therapy versus treatment as usual: results of a multisite randomized trial for substance using adolescents. J Consult Clin Psychol (2011) 1.23

Measures such as interstate cooperation would improve the efficacy of programs to track controlled drug prescriptions. Health Aff (Millwood) (2013) 1.22

Concussion in professional football: injuries involving 7 or more days out--Part 5. Neurosurgery (2004) 1.21

Management practices in substance abuse treatment programs. J Subst Abuse Treat (2009) 1.21

Serious adverse events in randomized psychosocial treatment studies: safety or arbitrary edicts? J Consult Clin Psychol (2008) 1.20

Estimating the client costs of addiction treatment: first findings from the client drug abuse treatment cost analysis program (Client DATCAP). Drug Alcohol Depend (2003) 1.19

Long-term user perceptions of an implanted neuroprosthesis for exercise, standing, and transfers after spinal cord injury. J Rehabil Res Dev (2003) 1.19

Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biol Psychiatry (2012) 1.18

Mindfulness meditation for alcohol relapse prevention: a feasibility pilot study. J Addict Med (2008) 1.18

Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend (2005) 1.18